Bristol-Myers Squibb invested $3.7 billion in 2013 to discover and develop innovative medicines to help patients prevail against serious diseases.
In the past several years, we have delivered a number of new products for patients in need, including medicines for rheumatoid arthritis, hepatitis B, cancer, HIV/AIDS and diabetes. As we look to the future, our pipeline
continues to expand as we have approximately 55 compounds in development, of which, nearly half are biologics. Below is a list of the disease areas in which we focus:
- Fibrotic Diseases
- Exploratory Areas
In the true spirit of science, we are dedicated sharing our clinical trials information and data with patients, medical/research communities, the media, policy makers and the general public, consistent with the Principles for Responsible Clinical Trial Data Sharing (Principles) released by the U.S. and European pharmaceutical trade associations, PhRMA and EFPIA, which support the safeguarding of patient privacy and informed consent, respecting the integrity of national regulatory systems and maintaining incentives for investment in biomedical research.
We act on our belief that the priceless ingredient of every product is the integrity of its maker.